Oxypeucedanin

Oxypeucedanin is a furanocoumarin derivative found in Angelica dahurica. Oxypeucedanin is an orally active PI3K/AKT/NF-κB, MAPK, and ROS inhibitor. Oxypeucedanin induces cell cycle arrest and apoptosis. Oxypeucedanin inhibits hKv1.5 channel currents (IC50: 76 nM) . Oxypeucedanin exhibits anticancer, anti-inflammatory, antioxidant and antiarrhythmic activities[1][2][3][4][5].

Product Specifications

CAS Number

[737-52-0]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Akt; Apoptosis; COX; ERK; JNK; NF-κB; NO Synthase; p38 MAPK; PI3K; Potassium Channel

Type

Natural Products

Related Pathways

Apoptosis; Immunology/Inflammation; MAPK/ERK Pathway; Membrane Transporter/Ion Channel; NF-κB; PI3K/Akt/mTOR; Stem Cell/Wnt

Applications

Cancer-programmed cell death

Field of Research

Cancer; Inflammation/Immunology; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/oxypeucedanin.html

Purity

99.50

Solubility

DMSO : 12.5 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

CC1(C)C(O1)COC2=C(C=CO3)C3=CC(O4)=C2C=CC4=O

Molecular Formula

C16H14O5

Molecular Weight

286.28

Precautions

H302, H315, H319, H335

References & Citations

[1]Eun JS, et al. Effects of oxypeucedanin on hKv1.5 and action potential duration. Biol Pharm Bull. 2005 Apr;28 (4) :657-60.|[2]Kang TJ, et al. Anti-tumor activity of oxypeucedanin from Ostericum koreanum against human prostate carcinoma DU145 cells. Acta Oncol. 2009;48 (6) :895-900.|[3]Du L, et al. Oxypeucedanin relieves LPS-induced acute lung injury by inhibiting the inflammation and maintaining the integrity of the lung air-blood barrier. Aging (Albany NY) . 2022 Aug 18;14 (16) :6626-6641.|[4]Liu M, et al. Oxypeucedanin hydrate alleviates rheumatoid arthritis by inhibiting the TLR4-MD2/NF-κB/MAPK signaling axis. Acta Biochim Biophys Sin (Shanghai) . 2024 May 11;56 (12) :1789-1801.|[5]Zheng MC, et al. Preclinical Pharmacokinetics and Bioavailability of Oxypeucedanin in Rats after Single Intravenous and Oral Administration. Molecules. 2022 Jun 2;27 (11) :3570.